IL13 and central nervous system cancer: In particular, monoclonal antibodies specific for IL-13Rα2, which disrupt IL-13/IL-13Rα2 interactions, improved the survival of mice with orthotopic glioma xenografts [56] and inhibited liver metastasis of colorectal cancer cells expressing IL13Rα2 [45].